Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 15.46 -0.96% -0.15
HALO closed up 2.5 percent on Tuesday, May 21, 2019, on 89 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical HALO trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -0.96%
Cup with Handle Other -0.96%
Oversold Stochastic Weakness -0.96%
Cup with Handle Other 1.51%
Below Lower BB Weakness 1.51%
Lower Bollinger Band Touch Weakness 1.51%
Oversold Stochastic Weakness 1.51%
Cup with Handle Other -0.96%
Oversold Stochastic Weakness -0.96%
Stochastic Buy Signal Bullish -2.89%

Older signals for HALO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Solid Tumors Antibodies Diabetes Mellitus Clinical Trial Product Hoffmann La Roche Halozyme Hyaluronidase
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 19.56
52 Week Low 13.24
Average Volume 778,308
200-Day Moving Average 16.4354
50-Day Moving Average 16.315
20-Day Moving Average 16.192
10-Day Moving Average 15.878
Average True Range 0.5071
ADX 14.87
+DI 17.5745
-DI 26.3913
Chandelier Exit (Long, 3 ATRs ) 15.9087
Chandelier Exit (Short, 3 ATRs ) 16.7363
Upper Bollinger Band 17.2269
Lower Bollinger Band 15.1571
Percent B (%b) 0.22
BandWidth 12.782856
MACD Line -0.241
MACD Signal Line -0.1336
MACD Histogram -0.1074
Fundamentals Value
Market Cap 2.09 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -16.78
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.33
Resistance 3 (R3) 16.29 16.02 16.21
Resistance 2 (R2) 16.02 15.83 16.04 16.17
Resistance 1 (R1) 15.81 15.72 15.92 15.85 16.13
Pivot Point 15.54 15.54 15.59 15.56 15.54
Support 1 (S1) 15.33 15.35 15.44 15.37 15.09
Support 2 (S2) 15.06 15.24 15.08 15.05
Support 3 (S3) 14.85 15.06 15.01
Support 4 (S4) 14.89